ORYZON GENOMICS (ORY) announced on Monday that the Japan Patent Office has issued a Grant Decision for patent application JP2021-557187, entitled ‘Combinations of iadademstat for cancer therapy,’ strengthening the global protection of its iadademstat compound. Once the formal grant is issued, the company expects the patent to remain in force until at least 2040, excluding any possible extension of its term. With this decision, ORY has secured patent protection for…

Link Securities | Oryzon’s Extraordinary General Shareholders’ Meeting has approved, among other matters, a capital increase of up to €125 million, as reported by the company through the National Securities Market Commission (CNMV). Specifically, it has approved “a capital increase, through cash contributions and with the exclusion of pre-emptive subscription rights, in an effective amount of up to €125 million and delegation to the Board of Directors of the power…